Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

MADD Survey Reveals Need to Educate About Dangers of Prescription Drug Consumption and Driving

Combining Impairing Substances Is a Growing Problem Nationwide


News provided by

MADD

Sep 22, 2021, 15:15 ET

Share this article

Share toX

Share this article

Share toX


DALLAS, Sept. 22, 2021 /PRNewswire-PRWeb/ -- One in 20 U.S. adults admits to driving within two hours of consuming prescription medications that cause impairment, according to a new survey commissioned by Mothers Against Drunk Driving (MADD). About one in five adults have, or know someone who has, driven while impaired by prescription opioids, depressants, or stimulants – or those mixed with other substances like alcohol or marijuana.

The nationwide survey by IPSOS, a global leader in market research, comes amid reports of increased drug use among drivers seriously or fatally injured in car crashes in 2020. According to the National Highway Traffic Safety Administration, 64% of seriously and fatally injured drivers tested at five major trauma centers during the second quarter of 2020 had at least one impairing substance in their system, including opioids, marijuana, alcohol, stimulants, and anti-depressants. The presence of opioids among those drivers jumped from 6.8% in the fourth quarter of 2019 to over 14% in the second and third quarters of 2020, and over 9% in the first and fourth quarters.

“We are seeing a terrifying rise in the number of people consuming impairing prescription drugs and driving. We are deeply concerned about the combination of alcohol consumption and other drugs, such as prescription medications, increasing the risk of tragedies on our roads.”

Post this

"We are seeing a terrifying rise in the number of people consuming impairing prescription drugs and driving," said MADD National President Alex Otte. "What's even more dangerous is poly-drugged driving - combining a mixture of alcohol, marijuana and/or prescription drugs. We are deeply concerned about the combination of alcohol consumption and other drugs, such as prescription medications, increasing the risk of tragedies on our roads."

According to NHTSA, 22% or more of the drivers tested at the five trauma centers throughout 2020 had multiple drugs in their system. Even so, according to the IPSOS survey, 85% of U.S. adults say they would be very uncomfortable riding in a vehicle with someone who had recently consumed a combination of drugs, including alcohol.

To keep our nation's highways safe, MADD is embarking on a broad initiative to educate all U.S. drivers of the dangers of driving under the influence of alcohol, marijuana, and prescription medications. Through program enhancements, public outreach and corporate alliances, MADD will continue its fight to eliminate drunk and drug-impaired driving.

MADD commissioned IPSOS in June 2021 to conduct a nationwide study of approximately 2,000 people ages 18 and older using the KnowledgePanel. The research was aimed at understanding the attitudes and behaviors related to driving under the influence of prescription medications, along with knowledge of the laws that surround it.

"MADD is concerned that there is a clear lack of understanding about the risks of prescription medications causing impairment while driving," Otte said. "The survey highlights the confusion that exists and the alarming number of people who are consuming prescription medications and driving."

Additional findings include:

  • About one in five have, or know someone who has, driven while impaired by prescription opioid (18%), depressant (18%), or stimulant medications (17%) – or those mixed with other substances like alcohol or marijuana (22%)
  • One in 20 admit to personally driving within two hours of consuming prescription medications that can cause impairment:
  • Opioids (6%), depressants (6%), and stimulants (4%), while slightly more (7%) admit to poly-drugged driving.
  • 48% of parents and grandparents say that conversations about poly-drugged driving should happen in middle school, yet just 25% report actually doing so in middle school and 38% have not had this conversation.
  • Three in four US adults agree that they don't hear much about driving under the influence of prescription medication in the news today (73%) and that additional research on the subject is needed (75%).
  • Only 50% view driving impaired from Opioid Rx med use as a serious crime, while 17% say it is only a minor traffic offense, 25% are unsure and 7% think it's legal.

"Road safety is more than just vehicle features and technology. It's also about initiatives to support safe driving behaviors," said John Capp, GM's director of Global Safety Technology, Strategy and Regulations. "Through Periscope, GM's new safety brand, GM works with nonprofit organizations to help educate and promote the safety of drivers, passengers, children, cyclists and pedestrians. GM and Periscope are proud to support this research by MADD that can help identify the issue and inform drivers on the dangers of impaired driving."

"MADD thanks General Motors for their support in funding this important project. We are so grateful for their dedication to our shared mission to stop these tragedies that destroy families and devastate our communities," Otte said.

To review the survey results, visit https://www.madd.org/the-solution/drugged-driving-prevention/

1. This survey was conducted June 4th – 6th, 2021, during the widespread impacts of the coronavirus pandemic in the US. It is viewed as a baseline of perceptions and attitudes.

About Mothers Against Drunk Driving
Founded in 1980 by a mother whose daughter was killed by a drunk driver, Mothers Against Drunk Driving® (MADD) is the nation's largest nonprofit working to end drunk driving, help fight drugged driving, support the victims of these violent crimes, and prevent underage drinking. MADD has helped save more than 400,000 lives, reduce drunk driving deaths by more than 50 percent and promote designating a non-drinking driver. MADD's Campaign to Eliminate Drunk Driving® calls for law enforcement support, ignition interlocks for all offenders and advanced vehicle technology. MADD has provided supportive services to nearly one million drunk and drugged driving victims and survivors at no charge through local victim advocates and the 24-Hour Victim Help Line 1-877-MADD-HELP (877-623-3435). Visit http://www.madd.org or call 1-877-ASK-MADD (877-275-6233).

About General Motors
General Motors (NYSE:GM) is a global company focused on advancing an all-electric future that is inclusive and accessible to all. At the heart of this strategy is the Ultium battery platform, which will power everything from mass-market to high-performance vehicles. General Motors, its subsidiaries and its joint venture entities sell vehicles under the Chevrolet, Buick, GMC, Cadillac, Baojun and Wuling brands. More information on the company and its subsidiaries, including OnStar, a global leader in vehicle safety and security services, can be found at https://www.gm.com.

Media Contact

Becky Iannotta, MADD, 202.600.2032, [email protected]

Twitter, Facebook

SOURCE MADD

Related Links

http://www.madd.org

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.